[{"id":"e9dfca51-3f27-45f4-a40b-0bf4c8ceb200","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576871","created_at":"2021-01-18T21:50:54.507Z","updated_at":"2024-07-02T16:35:30.905Z","phase":"Phase 1","brief_title":"Re-treatment 225Ac-J591 for mCRPC","source_id_and_acronym":"NCT04576871","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/29/2020","start_date":" 10/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-31"},{"id":"bb9b1fd6-07d2-4950-8e57-40864d118e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04506567","created_at":"2021-01-18T21:36:26.540Z","updated_at":"2024-07-02T16:35:38.849Z","phase":"Phase 1/2","brief_title":"Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC","source_id_and_acronym":"NCT04506567","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 08/18/2020","start_date":" 08/18/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2023-08-28"},{"id":"1b36b4ee-0095-44fb-b7a3-0681f98a1eb6","acronym":"ACTION","url":"https://clinicaltrials.gov/study/NCT05567770","created_at":"2022-10-05T12:55:59.042Z","updated_at":"2024-07-02T16:35:39.145Z","phase":"Phase 1","brief_title":"ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer","source_id_and_acronym":"NCT05567770 - ACTION","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-08-24"},{"id":"f2afbf99-2029-4f29-86c4-41a5cc58b54c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886986","created_at":"2021-05-14T12:52:39.196Z","updated_at":"2024-07-02T16:35:39.458Z","phase":"Phase 1/2","brief_title":"Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I\u0026T for Progressive Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT04886986","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Suspended","enrollment":" Enrollment 48","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 12/27/2027","study_completion_date":" 12/27/2027","last_update_posted":"2023-08-21"}]